Revisiting the Significance of Warfarin Protein-Binding Displacement Interactions

Chan TY . Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: Mechanism, clinical significance, and avoidance. Ann Pharmacother 1995;29: 1274–83.

Sellers EM Koch-Weser J . Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs. Ann N Y Acad Sci 1971;179: 213–23.

Koch-Weser J Sellers EM . Drug interactions with coumarin anticoagulants. N Engl J Med 1971;285: 547–58.

Gillette JR . Overview of factors affecting drug interactions. Ann N Y Acad Sci 1976;281: 136–50.

Serlin MJ Breckenridge AM . Drug interactions with warfarin. Drugs 1983;25: 610–20.

MacKichan JJ . Pharmacokinetic consequences of drug displacement from blood and tissue proteins. Clin Pharmacokinet 1984;9(suppl 1):32–41.

MacKichan JJ . Protein-binding drug displacement interactions: Fact or fiction? Clin Pharmacokinet 1989;16: 65–73.

MacKichan JJ . Influence of protein-binding and use of unbound (free) drug concentration. In: Evans WE Schentag JJ Jusko WJ , eds. Applied pharmacokinetics: Principles of therapeutic drug monitoring. 3rd ed. Vancouver, WA: Applied Therapeutics, 1992:5–1–5–48.

Porter RS Sawyer WT . Warfarin. In: Evans WE Schentag JJ Jusko WJ , eds. Applied pharmacokinetics: Principles of therapeutic drug monitoring. Vancouver, WA: Applied Therapeutics, 1992:31–1–31–46.

Gibaldi M Koup JR . Pharmacokinetic concepts: Drug binding, apparent volume of distribution, and clearance. Eur J Clin Pharmacol 1981;20: 299–305.

Johnson AG Seiderman P Day RO . Adverse drug interactions with nonsteroidal anti-inflammatory drugs (NSAIDs): Recognition, management and avoidance. Drug Saf 1993;8: 99–127.

Bauer LA . Clinical pharmacokinetics and pharmacodynamics. In: Dipiro JJ Talbert RL Yee GC Matzke GR Wells BG Posey LM , eds. Pharmacotherapy: A pathophysiologic approach. 4th ed. Stanford, CT: Appleton and Lange, 1999: 21–43.

Wilkinson GR Shand DG . Commentary. A physiologic approach to hepatic drug clearance. Clin Pharmacol Ther 1975;18: 377–90.

Levy G . Effects of plasma protein-binding of drugs on duration and intensity of pharmacologic activity. J Pharm Sci 1976;65: 1264–5.

Serlin MJ Mossman S Sibeon RG Tempero KF Breckenridge AM . Interaction between diflunisal and warfarin. Clin Pharmacol Ther 1980;28: 493–8.

Donaldson DR Sreeharan N Crow MJ Rajah SM . Assessment of the interaction of warfarin with aspirin and dipyridamole. Thrombos Haemostas 1982;47: 77–80.

Johnson AG Day RO . The problems and pitfalls of NSAID therapy in the elderly (part I). Drug Aging 1991;1: 130–43.

Toon S Low LK Gibaldi M Trager WF O'Reilly RA . The warfarin—sulfinpyrazone interactions: Steriochemical considerations. Clin Pharmacol Ther 1986;39: 15–24.

Schwartz JI Bugianesi KJ Ebel DL DeSmet M Haesen R Larson PJ The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin. Clin Pharmacol Ther 2000;68: 626–36.

Karim A Tolbert D Piergies A Hubbard RC Harper K Wallemark CB Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects. J Clin Pharmacol 2000;40: 655–63.

Package insert. Celebrex (celecoxib). Chicago: GD Searle, May 21, 1999.

Haase KK Rojas-Fernandez CH Lane L Frank DA . Potential interaction between celecoxib and warfarin (letter). Ann Pharmacother 2000;34: 666–7.

Mersfelder TL Stewart LR . Warfarin and celecoxib interaction. Ann Pharmacother 2000;34: 325–7.

Health care professional advisory letter. May 1999. Searle and Pfizer [cited 2002 Sep 3]. Available from: URL: http://www.fda.gov/medwatch/safety/1999/celebr.htm.

Hinz B Brane K . Cyclooxygenase-2-10 years later. J Pharmacol Exp Ther 2002;300: 367–75.

Redman AR . Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy 2001;21: 235–42.

Kaminsky LS Zhang ZY . Human P450 metabolism of warfarin. Pharmacol Therapeut 1997;73: 67–74.

Kimura M Ieiri I Mamiya K Urae A Higuchi S . Genetic polymorphism of cytochrome P450s, CYP2C19 and CYP2C9 in a Japanese population. Ther Drug Monit 1998;20: 243–7.

Furaya H Fernandez-Salguero P Gregory W . Genetic polymorphisms of CYP2C9 and its effect on warfarin maintenance dose requirements in patients undergoing anticoagulation therapy. Pharmacogenetics 1995;5: 389–92.

Aithal GP Day CP Kesteren PJ Daly AK . Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirements and risk of bleeding complications. Lancet 1999;353: 717–9.